Literature DB >> 10438511

Chemical probes that differentially modulate peroxisome proliferator-activated receptor alpha and BLTR, nuclear and cell surface receptors for leukotriene B(4).

P R Devchand1, A K Hihi, M Perroud, W D Schleuning, B M Spiegelman, W Wahli.   

Abstract

Peroxisome proliferator-activated receptor alpha (PPARalpha)is a nuclear receptor for various fatty acids, eicosanoids, and hypolipidemic drugs. In the presence of ligand, this transcription factor increases expression of target genes that are primarily associated with lipid homeostasis. We have previously reported PPARalpha as a nuclear receptor of the inflammatory mediator leukotriene B(4) (LTB(4)) and demonstrated an anti-inflammatory function for PPARalpha in vivo (Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., and Wahli, W. (1996) Nature 384, 39-43). LTB(4) also has a cell surface receptor (BLTR) that mediates proinflammatory events, such as chemotaxis and chemokinesis (Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y., and Shimizu, T. (1997) Nature 387, 620-624). In this study, we report on chemical probes that differentially modulate activity of these two LTB(4) receptors. The compounds selected were originally characterized as synthetic BLTR effectors, both agonists and antagonists. Here, we evaluate the compounds as effectors of the three PPAR isotypes (alpha, beta, and gamma) by transient transfection assays and also determine whether the compounds are ligands for these nuclear receptors by coactivator-dependent receptor ligand interaction assay, a semifunctional in vitro assay. Because the compounds are PPARalpha selective, we further analyze their potency in a biological assay for the PPARalpha-mediated activity of lipid accumulation. These chemical probes will prove invaluable in dissecting processes that involve nuclear and cell surface LTB(4) receptors and also aid in drug discovery programs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438511     DOI: 10.1074/jbc.274.33.23341

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Zileuton, a new efficient and safe systemic anti-acne drug.

Authors:  Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2009-05

2.  Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886.

Authors:  J P Kehrer; S S Biswal; E La; P Thuillier; K Datta; S M Fischer; J P Vanden Heuvel
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

Review 3.  High density lipoprotein, apolipoprotein A-I, and coronary artery disease.

Authors:  R A Srivastava; N Srivastava
Journal:  Mol Cell Biochem       Date:  2000-06       Impact factor: 3.396

4.  A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders.

Authors:  T Yokomizo; K Kato; K Terawaki; T Izumi; T Shimizu
Journal:  J Exp Med       Date:  2000-08-07       Impact factor: 14.307

Review 5.  The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond.

Authors:  Pallavi R Devchand; Tianyun Liu; Russ B Altman; Garret A FitzGerald; Eric E Schadt
Journal:  Front Pharmacol       Date:  2018-10-04       Impact factor: 5.810

6.  Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling.

Authors:  Maryam Rakhshandehroo; Linda M Sanderson; Merja Matilainen; Rinke Stienstra; Carsten Carlberg; Philip J de Groot; Michael Müller; Sander Kersten
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.